We've been over this already - there is a big misunderstanding here that the accelerated approval means the heart failure indication will be commercialised soon - this is not the case. Again IMO.
The evidence is not there - they failed the first study, found some interesting potential areas to investigate further, and have now discussed the potential for accelerated approval - meaning approval based on a surrogate endpoint for a future study. They won't do this retrospectively, that's not how it works.
So that is still years and many cap raises away.
A lot of this is absolutely hype. This is a billion dollar company bleeding money left and right and continue to fail to prove their products work.
Maybe third times the charm
imo.
good luck
I hope I'm wrong
Ann: FDA Accepts Mesoblast's BLA Resubmission for Remestemcel-L, page-131
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.33 |
Change
0.088(7.03%) |
Mkt cap ! $1.575B | |||
| Open | High | Low | Value | Volume |
| $1.27 | $1.40 | $1.27 | $11.98M | 8.901M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 18 | 186925 | $1.33 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.34 | 20532 | 8 |
View Market Depth
| Last trade - 13.17pm 03/10/2024 (20 minute delay) ? |
| MSB (ASX) Chart |